Reading a Dementia Care Plan: Questions Families Ask About Medicines and Follow-Up

The folder comes home in a tote bag with the discharge papers, a parking stub, and a pharmacy leaflet folded into quarters. Somewhere inside is a page headed “Care Plan.” It lists a diagnosis, four medicines, a phrase about “community follow-up,” and a phone number that rings to a voicemail. The person it describes is sitting at the kitchen table asking whether anyone has fed the cat, which died in the spring.

This is the moment most families first meet the document that will shape the next several years. The most common dementia care plan questions are not about neurology. They are practical: Which of these tablets is for memory and which is for blood pressure? When do we know if the new one is working? Who do we call when Dad is more confused on a Sunday night?

This guide walks through a typical plan line by line, explains what the evidence says about the medicines it names, and shows how to turn a confusing page into a working tool for your family and your care team.

What is a dementia care plan, and what actually happens when one is written?

A dementia care plan is a written agreement between the person living with dementia, the people who support them, and the clinical team about what care will look like and who is responsible for each part. In practice it usually appears after a diagnosis is confirmed and again after any hospital stay or significant change.

The document is assembled from several conversations. A clinician records the type of dementia where it is known, because Alzheimer’s disease, vascular dementia, Lewy body dementia, and frontotemporal dementia behave differently and respond differently to medicines. A nurse or care coordinator adds the current medicine list, allergies, and any recent changes. Someone asks about the home: stairs, stove, driving, who else lives there, and what the person enjoys.

The goals section is the part families most often skip and most often need. It states, in plain language, what matters to the person: staying in their own home, keeping up a weekly card game, avoiding hospital where possible. Every later decision about medicines and follow-up should be tested against those goals.

Finally, the plan sets out the follow-up loop: who reviews the medicines, how often, and what should trigger an earlier call. MedlinePlus describes this coordinated approach as the standard framework for managing a long-term condition that changes over time, with the plan updated as needs shift rather than written once and filed.

What the plan is not: it is not a prognosis, not a legal document on its own, and not a promise about how the illness will unfold. It is a shared map, and like any map it is only useful if everyone is reading the same version.

Who usually gets a written plan, and who is asked to wait?

Anyone with a confirmed dementia diagnosis should have a care plan, and most health systems aim to review it at least once a year. The NHS describes an annual review as a routine expectation, with earlier contact when circumstances change. People newly discharged from hospital, those starting or stopping a dementia medicine, and those whose carer is struggling are typically prioritized for a fuller review.

Some people are asked to wait, and understanding why reduces frustration. Someone with mild cognitive impairment, which means measurable memory or thinking changes that do not yet interfere with daily life, may be monitored rather than given a full dementia plan. Mayo Clinic notes that mild cognitive impairment does not always progress to dementia, so clinicians often repeat assessments over months before labeling the condition.

Waiting is also common when a reversible cause has not been ruled out. Thyroid problems, vitamin B12 deficiency, depression, medication side effects, and untreated sleep apnea can all mimic dementia. A responsible team treats those first, then reassesses. A plan written too early can lock in a wrong diagnosis.

A third group asked to wait are people in the middle of an acute illness. Confusion during a urinary infection or after surgery is often delirium, a sudden and usually temporary disturbance of attention and awareness. Assessing memory during delirium gives a misleading picture, so teams typically wait several weeks after recovery before judging the underlying baseline.

If you feel your family member has been left waiting without explanation, ask two direct questions: What are we waiting to rule out, and what date do we expect a decision? Both are reasonable, and both deserve a clear answer.

Dementia care plan questions about medicines: what each class does

Most plans for Alzheimer’s disease and several related dementias list one of two medicine classes, and understanding them removes a great deal of anxiety.

Cholinesterase inhibitors work by slowing the breakdown of acetylcholine, a chemical messenger that nerve cells use to communicate and that declines in Alzheimer’s disease. The National Institute on Aging explains that these medicines may help with memory, attention, and some daily tasks for a period of time in people with mild to moderate disease, but they do not stop the underlying process. Common generic names in this class include donepezil, rivastigmine, and galantamine. The most frequent side effects are nausea, loose stools, reduced appetite, and vivid dreams, and a slowed heart rate is a recognized concern that clinicians check for.

The second class contains a single widely used medicine, memantine, which acts on a different messenger called glutamate. Too much glutamate activity can damage nerve cells; memantine dampens that signal. It is usually considered in moderate to severe disease, sometimes alongside a cholinesterase inhibitor.

Newer antibody treatments that target amyloid protein deposits exist for early Alzheimer’s disease in some regions. They are given by infusion, require imaging checks for brain swelling or small bleeds, and are suitable only for a specific group after specialized testing. If one appears in a plan, ask the team to explain the monitoring schedule in detail.

What none of these medicines do is reverse dementia or work for every type. Cholinesterase inhibitors are not routinely used for frontotemporal dementia, for instance, and can worsen some symptoms there. Whether any of them is right, and for how long, is a decision that belongs to the prescribing clinician, informed by what you observe at home.

How long do dementia medicines take to work, and how will we know?

Families often expect a memory medicine to behave like an antibiotic: take it, see improvement, done. The reality is quieter. The National Institute on Aging describes the benefit of cholinesterase inhibitors and memantine as modest and temporary, and Mayo Clinic notes that improvement, where it happens, may be small and may show up as stability rather than gains.

Clinicians typically assess response over a few months rather than weeks. The reason is that these medicines aim to hold a line, and you cannot see a line being held on day ten. A useful marker is whether daily function has stayed roughly where it was, whether the person seems more engaged, or whether a carer reports the days feel a little easier.

Because the effect is subtle, keep a simple record. Note two or three concrete things before starting: whether the person can still make tea unprompted, follow a television program, or find the bathroom at night. Recheck the same items at the review. This is far more useful to the team than a general sense that things are “about the same.”

Ask the plan to answer three questions in writing: what change we are hoping for, when the team will judge whether it has happened, and what would make them consider stopping. Stopping a dementia medicine is a legitimate clinical decision, particularly in advanced disease when swallowing becomes difficult or side effects outweigh any benefit. It should be made by the prescriber, ideally with a planned check afterward, because some people decline noticeably when a medicine is withdrawn and the team may choose to restart it.

Never adjust, split, skip, or stop any medicine on your own judgment, even when it seems to do nothing. Report what you see and let the prescriber decide.

What is in a dementia care plan? A section-by-section checklist

Plans vary in layout, but the essential parts are consistent. Use the table below to check whether yours is complete and to spot what to ask about at the next appointment.

Plan section	What it should contain	Question to raise if missing or unclear
Diagnosis	Type of dementia where known, date, who made it, tests done	Is the type confirmed, or still being worked out?
Goals and preferences	What matters to the person, in their words where possible	Have we written down what a good day looks like?
Medicine list	Every medicine with its purpose, prescriber, and review date	Which of these is for memory, and what are the others for?
Risks and safety	Falls, wandering, driving, cooking, swallowing, weight	What has changed since the last assessment?
Behavior and mood	Triggers, what helps, agreed non-drug approaches	What should we try first before any new medicine?
Carer support	Named contact, respite options, carer’s own health	Who do we call, and when?
Advance planning	Power of attorney, wishes about hospital and future care	Has this been discussed while the person can still take part?
Follow-up	Date of next review, who leads it, triggers for earlier contact	What would make you want to see us sooner?

Two habits make the document work. First, ask for a single copy that is dated and replaced whenever anything changes, so nobody is reading an old medicine list. Second, keep it somewhere a visiting nurse, paramedic, or new doctor can find it: the fridge door is the traditional choice for good reason.

Cleveland Clinic and the NHS both emphasize that the plan belongs to the person and their family as much as to the team. If a section is blank, that blank is itself a question to bring to the next visit.

Why the medicine list includes drugs that have nothing to do with memory

A typical plan lists more medicines for other conditions than for dementia itself, and this surprises families who assumed the neurologist would focus only on the brain. It is deliberate.

Vascular risk factors matter for nearly every type of dementia. The American Heart Association’s guidance on brain health links high blood pressure, diabetes, high cholesterol, smoking, and atrial fibrillation to a greater risk of both stroke and cognitive decline. Controlling these conditions will not reverse existing damage, but it aims to reduce the chance of further vascular injury that could speed decline. So a blood pressure medicine, a statin, or a blood thinner may be as relevant to the plan as any memory drug.

Depression is common in dementia and can look like apathy or worsening memory. If an antidepressant appears, ask which symptoms it is targeting and how the team will judge whether it helped. Pain medicines matter too: untreated pain from arthritis or constipation is a frequent, overlooked cause of agitation, and treating it sometimes does more for behavior than any psychiatric medicine.

The list should also show what has been stopped and why. As dementia advances, the balance shifts. A medicine intended to prevent a problem ten years away may no longer make sense for someone whose goals have narrowed to comfort and staying home. Reducing this kind of burden is called deprescribing, meaning a planned, supervised reduction or withdrawal of medicines whose benefit no longer justifies their risk. It is a legitimate part of good care, not neglect.

Ask the prescriber to write the purpose beside each item in plain words. “For memory,” “for blood pressure,” “for mood” tells everyone in the household what they are handing over each morning and why.

Which medicines can worsen confusion, and why a dementia medication review matters

Some of the most important lines on a plan are the ones a good team removes. Certain everyday medicines make thinking worse in people with dementia, and a dementia medication review exists largely to find them.

Anticholinergic medicines block acetylcholine, the same messenger that cholinesterase inhibitors try to preserve. Giving both at once is like pressing the accelerator and brake together. Common culprits include some older antihistamines used in sleep aids and allergy tablets, certain bladder medicines for urgency, some older antidepressants, and a few medicines for dizziness or nausea. Mayo Clinic lists medication side effects among the reversible contributors to confusion for exactly this reason.

Sedatives and sleeping tablets, including benzodiazepines and related drugs, increase fall risk and can deepen daytime confusion. Opioid painkillers can cause drowsiness and constipation, which in turn worsen agitation. Some medicines for Parkinson’s symptoms may trigger hallucinations. None of this means these drugs are forbidden; it means every one needs a stated reason and a review date.

People with Lewy body dementia deserve special mention. They can react severely to many antipsychotic medicines, with sudden rigidity, sedation, or worsening confusion. If this diagnosis is suspected, it should be written prominently on the plan so that any clinician in an emergency department sees it before prescribing.

Bring everything to the review, including over-the-counter products, herbal supplements, and eye drops. Families routinely forget the sleep aid bought at the supermarket, which may be the most anticholinergic item in the house. The prescriber, not the family, decides what changes, but the review can only be as good as the list it starts from.

What the first weeks after a new care plan usually look like

The days after a new plan or a medicine change are often unsettled, and knowing what is typical prevents unnecessary alarm.

If a cholinesterase inhibitor has been started, the National Institute on Aging notes that stomach upset, reduced appetite, and disturbed sleep are the most common early effects. Prescribers usually begin at a low level and increase slowly over weeks precisely to let the body adjust; that schedule belongs to them, and families should follow the written instructions exactly rather than speeding up or slowing down. Taking the medicine with food, if the leaflet allows, is a common suggestion the team may make.

Behavior may shift before memory does. Some people become more alert and, paradoxically, more frustrated because they are more aware of their difficulties. Others sleep differently. Note what you see and when, and share it at the follow-up call that most plans schedule within the first few weeks of any change.

Practical routines matter more than most families expect. A pill organizer filled by one named person, a written time on the fridge, and a daily tick sheet reduce the two most common problems: missed doses and doubled doses. If the person handles their own tablets, a locked box or a pharmacy blister pack may be discussed with the team.

The home changes too. This is the window when occupational therapy, a professional assessment of how someone manages daily tasks at home, is most useful, along with a falls check and a conversation about driving where relevant.

Expect the first review to feel like a status report rather than a verdict. The team is calibrating, and your notes are their most valuable instrument.

Dementia follow-up appointments: how often, and what happens at a review

Follow-up frequency depends on stage, stability, and local services, but a few patterns hold. The NHS describes a formal review at least once a year for everyone with a dementia diagnosis, with more frequent contact after a diagnosis, a hospital stay, or a change in medicines. Some memory services see people every few months in the first year; primary care then often takes over the routine review.

A well-run review covers more than memory tests. Expect the clinician to ask about eating and weight, sleep, mood, continence, falls, pain, and how the carer is coping. Weight loss in particular is a red flag the team watches, because it may signal swallowing trouble, forgotten meals, depression, or a medicine side effect. Blood pressure and pulse are usually checked, especially for anyone on a cholinesterase inhibitor because of the effect on heart rate.

Cognitive screening tools may be repeated, but scores move slowly and are influenced by hearing, mood, and how the person slept. Do not read too much into a change of a point or two. Your account of daily function is often more informative than the score.

The medicine review sits at the heart of the appointment. Every item is checked for purpose, effect, side effects, and whether it still fits the person’s goals. This is where deprescribing decisions are made, and where the team may propose a trial of stopping something with a plan to watch closely.

Arrive with your dated notes, the current plan, and every medicine container in a bag. Ask for the updated plan before you leave, or a date by which it will be sent. A review that ends without a revised document has not quite finished.

Agitation, distress, and mood: why non-drug approaches usually come first

Behavior changes cause more distress to families than memory loss, and the plan should say clearly how they will be handled. Mainstream guidance from the NHS and Mayo Clinic is consistent: look for a cause, try non-drug approaches first, and reserve medicines for severe or dangerous situations.

Agitation is usually communication. Pain, constipation, a full bladder, hunger, noise, a room that is too hot or too dim, a carer’s rushed tone, or a sudden infection can all appear as pacing, shouting, or resistance. A plan that lists likely triggers for this particular person, and what has calmed them before, is worth more than any prescription.

Where medicines are considered, antidepressants are sometimes used for persistent low mood or anxiety. Antipsychotic medicines, which act on dopamine signaling in the brain, carry a documented increase in the risk of stroke and death in older people with dementia, a warning that regulators including the US Food and Drug Administration require on their labeling and that Mayo Clinic highlights. Guidance therefore restricts them to situations of severe distress or risk of harm, at the lowest effective level, for the shortest time, with a set review date. If one appears on a plan, the plan should also say when it will be reconsidered.

Sleep problems are common. Rather than sedatives, teams usually start with daylight exposure, daytime activity, limiting naps and caffeine, and a consistent bedtime routine. Melatonin is sometimes discussed, though evidence for benefit in dementia is mixed; ask the team what the research actually supports.

The guiding principle: the person is not being difficult, they are having difficulty. A plan written in that spirit tends to reach for medicine far less often.

Capacity, advance care planning, and who signs off on decisions

A care plan for a progressive condition must look ahead, and this is the section families find hardest to open. It is also the one they later say they were most grateful for.

Mental capacity means the ability to understand, retain, and weigh information to make a specific decision, and to communicate the choice. Capacity is decision-specific: someone may be unable to manage finances yet perfectly able to say they want to stay in their own home. Early in dementia, most people can take part in planning their future, and MedlinePlus and the NHS both encourage those conversations while that is still possible.

Advance care planning covers three practical areas. A durable power of attorney for health care names someone to make medical decisions if the person cannot. A financial power of attorney does the same for money. An advance directive or living will records wishes about treatments such as feeding tubes, resuscitation, and hospital transfer. Terminology and legal forms differ by state and country, so ask the team who can help complete them correctly.

The plan should record where these documents are kept and who holds copies. It should also note the person’s own words about what they want, because a paragraph in their voice guides future clinicians better than a checkbox.

None of this removes the person from decisions about their own care. Even in later stages, preferences about food, music, routine, and who provides personal care can and should be honored. The team’s job is to keep the person at the center for as long as possible, and the family’s job is to keep reminding everyone who that person is.

What people often get wrong about dementia care plans and medicines

Some myths cause real harm, and a good plan quietly dismantles them.

“The memory pill will bring them back.” The National Institute on Aging is explicit that current medicines may ease symptoms for a time but do not reverse or halt Alzheimer’s disease. Expecting a return to the person of five years ago sets families up for grief on top of grief. Stability is the realistic hope.

“If it isn’t working, we should just stop it.” Effects are subtle, and stopping can cause a noticeable decline. That judgment belongs to the prescriber, made with a plan to watch what happens.

“Supplements are safer than prescriptions.” The NIH Office of Dietary Supplements finds no convincing evidence that ginkgo, vitamin E, fish oil, or similar products improve or prevent dementia, and some interact with prescribed medicines or increase bleeding risk. Every supplement belongs on the medicine list.

“More confusion means the dementia is progressing.” Sudden worsening over hours or days is far more often delirium from infection, dehydration, constipation, pain, or a new medicine. Dementia itself changes over months, not overnight. A sudden change is a reason to call, not to accept.

“The plan is the doctor’s document.” It is a shared tool. You are entitled to a copy, to ask for changes, and to have the person’s goals written into it.

“Antipsychotics are the treatment for agitation.” They are a last resort with documented risks, used briefly and reviewed. The first-line approach is finding the cause.

“Nothing can be done.” Vascular risk control, hearing correction, treating depression, exercise, social contact, and a safe home all shape how the condition unfolds. The plan exists precisely because a great deal can be done.

Questions to ask your dementia doctor at the next review

Walk in with a short written list. Clinicians consistently say that prepared families get more from an appointment, and a list keeps the conversation from drifting into whatever happened that morning.

About the diagnosis: Is the type of dementia confirmed, and does it affect which medicines are suitable? Have reversible causes such as thyroid problems, B12 deficiency, depression, and medication effects been ruled out?

About each medicine: What is this for, in one sentence? What change are we hoping to see, and by when will you judge it? What side effects should we watch for at home? Is there anything on the list that may be making confusion worse? Which medicines could we consider stopping as things change, and how would that be done safely?

About behavior and mood: What do you think is driving the agitation, and what should we try first? If a medicine is ever needed for distress, how long would it be used and when would it be reviewed?

About follow-up: When is the next review, who leads it, and what should make us call sooner? Who do we contact out of hours, and what will they need to know?

About the future: Has advance care planning been discussed? Where are the documents, and does the plan say what the person wants if they become seriously ill?

About us: What support exists for carers, and how do we access respite? Is there a named coordinator?

Take notes or ask permission to record the answers. Ask for the revised plan in writing. If a question cannot be answered on the day, ask who will follow up and by when. Leaving with a date is almost as valuable as leaving with an answer.

When to call your doctor: red-flag signs in dementia care

Most changes in dementia unfold slowly and can wait for the scheduled review. Some cannot. The distinction usually comes down to speed and severity.

Call the care team the same day, or use emergency services if the person seems very unwell, for any of the following: sudden confusion or drowsiness that developed over hours or a day or two, which suggests delirium from infection, dehydration, a medicine effect, or another acute illness; a fall with a head injury, especially in anyone taking a blood thinner; new weakness on one side, facial droop, slurred speech, or sudden vision loss, which are stroke warning signs that the American Heart Association says require immediate emergency care; a seizure; chest pain or severe shortness of breath; refusal of all food and fluids for more than a day; signs of infection such as fever, a new cough, painful or foul-smelling urine, or shaking; new hallucinations or severe agitation that puts the person or others at risk; or a suspected medication error, whether a missed day, a doubled dose, or the wrong tablets.

Contact the team within a few days, without waiting for the annual review, if you notice steady weight loss, coughing or choking when eating, new incontinence, a marked change in sleep, persistent low mood or talk of not wanting to live, wandering or getting lost, or a carer who feels unable to continue safely. Carer exhaustion is a clinical concern in its own right, not a private failing.

When you call, have the care plan in front of you and be ready to give the diagnosis, the full medicine list, what has changed, and how quickly. That information lets a clinician who has never met your family member make a safer decision in minutes. Any adjustment to medicines that follows should come from them, documented on an updated plan.

Frequently asked questions

What is a dementia care plan supposed to include?

A complete plan records the diagnosis and type of dementia, the person’s goals and preferences, every medicine with its purpose and review date, safety risks such as falls and driving, agreed approaches to mood and behavior, carer support contacts, advance care planning documents, and the date and lead clinician for the next review. If any section is blank, raise it at the next appointment.

How long does it take to know whether a dementia medicine is helping?

Clinicians typically judge response over a few months rather than weeks, because the aim is to hold function steady, and the National Institute on Aging describes the benefit as modest and temporary. Keep notes on two or three specific daily tasks before starting and compare them at the review. Decisions to continue or stop rest with the prescriber.

How often should dementia follow-up appointments happen?

At least once a year for a formal review, according to NHS guidance, with more frequent contact in the first months after diagnosis, after any hospital admission, and after a medicine is started, changed, or stopped. Many memory services see people every few months initially before routine care returns to the primary care team.

What happens at a dementia medication review?

The clinician checks every medicine, including over-the-counter and herbal products, for its purpose, effect, side effects, and whether it still fits the person’s goals. They look particularly for anticholinergic drugs, sedatives, and duplicated treatments, check pulse and blood pressure, and may propose supervised stopping of medicines whose benefit no longer justifies their risk.

What questions should I ask the dementia doctor about medicines?

Ask what each medicine is for in one sentence, what change is hoped for and by when, what side effects to watch at home, whether anything on the list could worsen confusion, and what would prompt the team to stop a medicine. Also ask who to call out of hours and when the next review is scheduled.

Can I stop a dementia medicine if it does not seem to be working?

No, not on your own judgment. The effect is often subtle and shows as stability rather than gains, and stopping can cause a noticeable decline that the team may want to watch for and reverse. Report what you observe, and let the prescribing clinician decide whether a supervised trial of stopping is appropriate.

Why does the care plan list blood pressure and cholesterol medicines?

Because vascular risk factors such as high blood pressure, diabetes, high cholesterol, smoking, and atrial fibrillation are linked to further brain injury and faster decline across most dementia types, according to the American Heart Association. Controlling them aims to protect what remains, so they are treated as part of dementia care rather than separate from it.

Are supplements like ginkgo or vitamin E useful for dementia?

The NIH Office of Dietary Supplements finds no convincing evidence that ginkgo, vitamin E, fish oil, or similar products improve or prevent dementia. Some interact with prescribed medicines or increase bleeding risk. Any supplement the person takes belongs on the medicine list so the team can check it at the review.

Is sudden worsening a sign the dementia is progressing quickly?

Usually not. Dementia changes over months; a change over hours or a day or two most often signals delirium caused by infection, dehydration, constipation, pain, or a new or changed medicine. This is a reason to contact the care team the same day, because the cause is frequently treatable and confusion often improves once it is addressed.

When are antipsychotic medicines used in dementia?

Only for severe distress, psychosis, or behavior that puts the person or others at risk, after causes such as pain and infection have been addressed and non-drug approaches tried. They carry a regulator-mandated warning about increased stroke and death risk in older people with dementia, so guidance calls for the shortest possible use with a set review date.

References

• National Institute on Aging (NIH): How Is Alzheimer's Disease Treated?
• NHS: Dementia, Care and Support
• MedlinePlus: Dementia
• Cleveland Clinic: Dementia

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.